{"id":"marketed-varicella-vaccine-lot-2","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Injection site reactions (erythema, swelling, pain)"},{"rate":"10-15","effect":"Fever"},{"rate":"3-5","effect":"Rash (vaccine strain)"},{"rate":"5-10","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains a weakened form of the varicella-zoster virus (VZV) that replicates in the body at low levels, triggering both humoral and cellular immune responses without causing clinical disease. This primes the immune system to recognize and rapidly respond to wild-type VZV infection, preventing or significantly reducing the severity of chickenpox and reducing the risk of herpes zoster (shingles) later in life.","oneSentence":"This live attenuated varicella-zoster virus vaccine stimulates the immune system to produce antibodies and cell-mediated immunity against varicella (chickenpox).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:50.468Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of varicella (chickenpox) in children and adults"},{"name":"Prevention of herpes zoster (shingles) in immunocompetent individuals"}]},"trialDetails":[{"nctId":"NCT06740630","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-01-10","conditions":"Chickenpox","enrollment":1840}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Marketed varicella vaccine_Lot 2","genericName":"Marketed varicella vaccine_Lot 2","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This live attenuated varicella-zoster virus vaccine stimulates the immune system to produce antibodies and cell-mediated immunity against varicella (chickenpox). Used for Prevention of varicella (chickenpox) in children and adults, Prevention of herpes zoster (shingles) in immunocompetent individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}